Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.
2.

Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Deane R, Bell RD, Sagare A, Zlokovic BV.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30. Review.

3.

Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.

Shackleton B, Crawford F, Bachmeier C.

Fluids Barriers CNS. 2016 Aug 8;13(1):14. doi: 10.1186/s12987-016-0038-x.

4.

Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).

Do TM, Dodacki A, Alata W, Calon F, Nicolic S, Scherrmann JM, Farinotti R, Bourasset F.

J Alzheimers Dis. 2016;49(2):287-300. doi: 10.3233/JAD-150350.

PMID:
26484906
5.

Clearance of amyloid-beta by circulating lipoprotein receptors.

Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV.

Nat Med. 2007 Sep;13(9):1029-31.

6.

LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model.

Nazer B, Hong S, Selkoe DJ.

Neurobiol Dis. 2008 Apr;30(1):94-102. doi: 10.1016/j.nbd.2007.12.005.

7.

Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.

Qosa H, Abuasal BS, Romero IA, Weksler B, Couraud PO, Keller JN, Kaddoumi A.

Neuropharmacology. 2014 Apr;79:668-78. doi: 10.1016/j.neuropharm.2014.01.023.

8.

Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.

Sagare AP, Deane R, Zlokovic BV.

Pharmacol Ther. 2012 Oct;136(1):94-105. doi: 10.1016/j.pharmthera.2012.07.008. Review.

9.

1,25-Dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing Aβ1-40 brain-to-blood efflux and peripheral uptake transport.

Guo YX, He LY, Zhang M, Wang F, Liu F, Peng WX.

Neuroscience. 2016 May 13;322:28-38. doi: 10.1016/j.neuroscience.2016.01.041.

PMID:
26820600
10.

Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia.

Yan FL, Zheng Y, Zhao FD.

Acta Neuropathol. 2008 Nov;116(5):529-35. doi: 10.1007/s00401-008-0435-6.

PMID:
18830615
11.

Lipopolysaccharide impairs amyloid β efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier.

Erickson MA, Hartvigson PE, Morofuji Y, Owen JB, Butterfield DA, Banks WA.

J Neuroinflammation. 2012 Jun 29;9:150. doi: 10.1186/1742-2094-9-150.

12.

Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.

Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V.

Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3510-5. doi: 10.1073/pnas.1112209109.

13.

Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease.

Jaya Prasanthi RP, Schommer E, Thomasson S, Thompson A, Feist G, Ghribi O.

Mech Ageing Dev. 2008 Nov;129(11):649-55. doi: 10.1016/j.mad.2008.09.002.

14.

Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV.

J Cereb Blood Flow Metab. 2007 May;27(5):909-18.

15.

Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway.

Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH.

J Clin Invest. 2000 Nov;106(9):1159-66.

16.

Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition.

Jaeger LB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-DeMotta MA, Lynch JL, Robinson SM, Niehoff ML, Johnson SN, Kumar VB, Banks WA.

J Alzheimers Dis. 2009;17(3):553-70. doi: 10.3233/JAD-2009-1074.

17.

Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.

Bell RD, Zlokovic BV.

Acta Neuropathol. 2009 Jul;118(1):103-13. doi: 10.1007/s00401-009-0522-3. Review.

19.

LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.

Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV.

Neuron. 2004 Aug 5;43(3):333-44.

20.

Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease.

Jaeger LB, Dohgu S, Sultana R, Lynch JL, Owen JB, Erickson MA, Shah GN, Price TO, Fleegal-Demotta MA, Butterfield DA, Banks WA.

Brain Behav Immun. 2009 May;23(4):507-17. doi: 10.1016/j.bbi.2009.01.017. Erratum in: Brain Behav Immun. 2011 Nov;25(8):1737. Butterfiled, D Allan [corrected to Butterfield, D Allan].

Items per page

Supplemental Content

Support Center